BRISTOL-MYERS SQUIBB CO (BMY)       72.45  -0.54 (-0.74%)

Company Profile

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in New York City, New York and currently employs 32,200 full-time employees. The firm is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. The company offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. The company also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Company Info

BRISTOL-MYERS SQUIBB CO

430 E. 29Th Street, 14 Floor

New York City NEW YORK 10016

P: 12125464000.0

CEO: Giovanni Caforio

Employees: 32200

Website: https://www.bms.com/